EUVIMEDEUVIMED entdecken
Fallbericht

Pseudoprogression of liver metastases and mixed response in primary gastric melanoma treated with nivolumab: A case report

Yusuke Seyama, Akinori Sugaya, Mikoto Fujihara, Hiroyuki Aikawa, Noa Yabana, Haruhisa Sugiyama, Hiroyuki Honda, Hajime Ishibashi, Masaharu Yamaoka, Mitsuharu Ozeki, Hitoaki Saito, Masahiro Araki und 2 weitere

Molecular and Clinical Oncology · 13.11.2026 · 26 (1) · 1-7

DOI: 10.3892/mco.2026.2987 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Molecular and Clinical Oncology, online erschienen am 13.11.2026. Verfasst von Yusuke Seyama und 13 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary gastric melanoma (PGM) is an extremely rare malignancy with a poor prognosis, and evidence regarding the efficacy of immune checkpoint inhibitors remains limited. The present report describes the case of a 70‑year‑old male patient with metastatic PGM who was treated with nivolumab monotherapy. Histopathological examination of a gastric tumor confirmed malignant melanoma, and staging studies revealed lymph node, lung and subsequent liver metastases. After nivolumab initiation, computed tomography demonstrated shrinkage of the primary gastric lesion but enlargement of metastatic lesions with the appearance of new liver and pleural metastases, resulting in a mixed response and progressive disease according to the Response Evaluation Criteria in Solid Tumors (RECIST). However, based on Immune RECIST (iRECIST), treatment was continued because pseudoprogression was suspected. Follow‑up imaging revealed regression of liver metastases after initial enlargement, consistent with site‑specific pseudoprogression, while disease control of the primary lesion, lymph node metastases and lung metastases was maintained for ~5 months. Although the disease eventually progressed because of pleural metastases, the present case demonstrated the potential clinical benefit of nivolumab in metastatic PGM. To the best of our knowledge, the present case may represent one of the few reported instances of site‑specific pseudoprogression and mixed response in PGM, and highlights the importance of iRECIST‑guided assessment to avoid premature discontinuation of immunotherapy.

Zitieren

APA

Seyama, Y., Sugaya, A., Fujihara, M., Aikawa, H., Yabana, N., Sugiyama, H., Honda, H., Ishibashi, H., Yamaoka, M., Ozeki, M., Saito, H., Araki, M., Goto, M., & Amagai, K. (2026). Pseudoprogression of liver metastases and mixed response in primary gastric melanoma treated with nivolumab: A case report. Molecular and Clinical Oncology, 26(1), 1-7. https://doi.org/10.3892/mco.2026.2987

Vancouver

Seyama Y, Sugaya A, Fujihara M, Aikawa H, Yabana N, Sugiyama H, et al. Pseudoprogression of liver metastases and mixed response in primary gastric melanoma treated with nivolumab: A case report. Molecular and Clinical Oncology. 2026;26(1):1-7. doi:10.3892/mco.2026.2987

BibTeX
@article{Seyama2026,
  author = {Seyama, Yusuke and Sugaya, Akinori and Fujihara, Mikoto and Aikawa, Hiroyuki and Yabana, Noa and Sugiyama, Haruhisa and Honda, Hiroyuki and Ishibashi, Hajime and Yamaoka, Masaharu and Ozeki, Mitsuharu and Saito, Hitoaki and Araki, Masahiro and Goto, Mitsuhide and Amagai, Kenji},
  title = {Pseudoprogression of liver metastases and mixed response in primary gastric melanoma treated with nivolumab: A case report},
  journal = {Molecular and Clinical Oncology},
  year = {2026},
  volume = {26},
  number = {1},
  pages = {1--7},
  doi = {10.3892/mco.2026.2987}
}
Kostenlos starten →